| abstract |
This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, R2a, L1, and R3, the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification. |